|
|
Article: ARIAD's AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor.
- Article from:
- Cancer Weekly
- Article date:
- November 17, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced that the scientific journal, Cancer Cell, has published a comprehensive paper describing the design and preclinical characterization of AP24534, ARIAD's investigational, multi-targeted kinase inhibitor. The paper, "AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance," is co-authored by scientists from ARIAD, and collaborating investigators from the Oregon Health & Science University Knight Cancer Institute and the Howard Hughes Medical Institute (see also ARIAD Pharmaceuticals).
The publication describes for the first time the ...
Related newspaper, magazine, and journal articles:
|